TCM
SRPT icon

Tekla Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Tekla Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-115,100
Closed -$1.53M – 131
2015
Q1 		$1.53M Buy
+115,100
New +$1.53M 0.06% 109
2014
Q4 		– Sell
-345,400
Closed -$7.29M – 110
2014
Q3 		$7.29M Buy
+345,400
New +$7.8M 0.34% 63

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tekla Capital Management's SRPT Position: Q2 2023 in Review

Tekla Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 37% in Q2 2023, selling an estimated $13.7M and leaving 179,437 shares worth $20.5M. The position accounts for 0.8% of the portfolio, ranked #35.

Tekla Capital Management first reported a position in SRPT in Q3 2014 and has held it in 31 quarters since. The position peaked at $39.4M in Q3 2021. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Tekla Capital Management held 179,437 shares of Sarepta Therapeutics worth $20.5M as of Q2 2023.
  • Tekla Capital Management sold 106,216 Sarepta Therapeutics shares in Q2 2023, an estimated $13.7M.
  • Sarepta Therapeutics made up 0.8% of Tekla Capital Management's portfolio in Q2 2023, its #35 holding.
  • Tekla Capital Management first reported a position in Sarepta Therapeutics in Q3 2014 and has held it in 31 quarters since.
  • Tekla Capital Management's Sarepta Therapeutics position peaked at $39.4M in Q3 2021.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.